CoChat
Sign Up
Cited by 34

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Exosome-based drug delivery systems for enhanced neurological therapeutics

Vahab, Safa A, V, Vyshma K, Kumar, Vrinda S·2025·Drug Delivery and Translational Research
DOI 10.1007/s13346-024-01710-x
Open this paper in CoChat — free account

Abstract

Exosomes are small extracellular vesicles naturally secreted by cells into body fluids, enriched with bioactive molecules such as RNAs, proteins, and lipids. These nanosized vesicles play a crucial role in physiological and pathological processes by facilitating intercellular communication and modulating cellular responses, particularly within the central nervous system (CNS). Their ability to cross the blood-brain barrier and reflect the characteristics of their parent cells makes exosomal cargo a promising candidate for biomarkers in the early diagnosis and clinical assessment of neurological conditions. This review offers a comprehensive overview of current knowledge on the characterization of mammalian-derived exosomes, their application as drug delivery systems for neurological disorders, and ongoing clinical trials involving exosome-loaded cargo. Despite their promising attributes, a significant challenge remains the lack of standardized isolation methods, as current techniques are often complex, costly, and require sophisticated equipment, affecting the scalability and affordability of exosome-based therapies. The review highlights the engineering potential of exosomes, emphasizing their ability to be customized for targeted therapeutic delivery through surface modification or conjugation. Future advancements in addressing these challenges and leveraging the unique properties of exosomes could lead to innovative and effective therapeutic strategies in neurology.

Overview

Integrity signals

Registry

Crossref · 10.1007/s13346-024-01710-x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 108

  1. Liu M-L, Williams KJ, Werth VP. Microvesicles in autoimmune diseases. Adv Clin Chem [Internet]. 2016;77:125–75. · DOI
  2. Battistelli M, Falcieri E. Apoptotic bodies: particular extracellular vesicles involved in intercellular communication. Biology (Basel). 2020;9:21.
  3. Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019;8:727. · DOI
  4. Kalluri R, Lebleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:6977. · DOI · Paper page
  5. Bagc C, Sever BM, Belder N, Bennett APS, Erdener SE, Dalkara T. Overview of extracellular vesicle characterization techniques and introduction to combined reflectance and fluorescence confocal microscopy to distinguish extracellular vesicle subpopulations. Neurophotonics. 2022;9:021903.
  6. Kamińska K, Godakumara K, Świderska B, Malinowska A, Midekessa G, Sofińska K, et al. Characteristics of size-exclusion chromatography enriched porcine follicular fluid extracellular vesicles. Theriogenology. 2023;205:79–86. · DOI
  7. Xiao L, Hareendran S, Loh YP. Function of exosomes in neurological disorders and brain tumors. Extracell Vesicles Circ Nucl Acids. 2021;2:55–79.
  8. Di Bella MA. Overview and update on extracellular vesicles: considerations on exosomes and their application in modern medicine. Biology (Basel). 2022;11:804.
  9. Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: key players in cancer and potential therapeutic strategy. Sig Transduct Target Ther. 2020;5:145. · DOI · Paper page
  10. Chen H, Wang L, Zeng X, Sekhar H, Zhou NY. Exosomes, a new star for targeted delivery. Front Cell Dev Biol. 2021;9: 751079.
  11. Shrivastava S, Morris KV. The multifunctionality of exosomes; from the garbage bin of the cell to a next generation gene and cellular therapy. Genes. 2021;12:173. · DOI
  12. Tenchov R, Sasso JM, Wang X, Liaw WS, Chen CA, Zhou QA. Exosomes─ nature’s lipid nanoparticles, a rising star in drug delivery and diagnostics. ACS Nano. 2022;16:17802–46. · DOI
  13. Kooijmans SA, de Jong OG, Schiffelers RM. Exploring interactions between extracellular vesicles and cells for innovative drug delivery system design. Adv Drug Delivery Rev. 2021;173:252–78. · DOI
  14. Gorshkov A, Purvinsh L, Brodskaia A, Vasin A. Exosomes as natural nanocarriers for RNA-based therapy and prophylaxis. Nanomaterials. 2022;12:524. · DOI
  15. Sen S, Xavier J, Kumar N, et al. Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. 3 Biotech. 2023;13:101. · DOI
  16. Lian MQ, Chng WH, Liang J, Yeo HQ, Lee CK, Belaid M, Tollemeto M, Wacker MG, Czarny B, Pastorin G. Plant-derived extracellular vesicles: Recent advancements and current challenges on their use for biomedical applications. J Extracell Vesicles. 2022;11:e12283. · DOI
  17. Mu N, Li J, Zeng L, You J, Li R, Qin A, Liu X, Yan F, Zhou Z. Plant-derived exosome-like nanovesicles: current progress and prospects. Int J Nanomed. 2023;18:4987–5009. · DOI
  18. Khan NA, Asim M, El Menyar A, Biswas KH, Rizoli S, Al TH. The evolving role of extracellular vesicles (exosomes) as biomarkers in traumatic brain injury: Clinical perspectives and therapeutic implications. Front Aging Neurosci. 2022;14:933434. · DOI
  19. Fan Y, Chen Z, Zhang M. Role of exosomes in the pathogenesis, diagnosis, and treatment of central nervous system diseases. J Transl Med. 2022;20:291. · DOI
  20. Rezaie J, Feghhi M, Etemadi T. A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal. 2022;20:145. · DOI
  21. Rajput A, Varshney A, Bajaj R, Pokharkar V. Exosomes as new generation vehicles for drug delivery: biomedical applications and future perspectives. Molecules. 2022;27(21):7289. · DOI
  22. Lee YJ, Shin KJ, Chae YC. Regulation of cargo selection in exosome biogenesis and its biomedical applications in cancer. Exp Mol Med. 2024;56:877–89. · DOI · Paper page
  23. Pishavar E, Trentini M, Zanotti F, Camponogara F, Tiengo E, Zanolla I, Bonora M, Zavan B. Exosomes as neurological nanosized machines. ACS Nanosci Au. 2022;2(4):284–96. · DOI
  24. Bandu R, Oh JW, Kim KP. Mass spectrometry-based proteome profiling of extracellular vesicles and their roles in cancer biology. Exp Mol Med. 2019;51:1–10. · DOI
  25. Keerthikumar S, Chisanga D, Ariyaratne D, et al. ExoCarta: a web-based compendium of exosomal cargo. J Mol Biol. 2016;428:688–92. · DOI
  26. Hade MD, Suire CN, Suo Z. Mesenchymal stem cell-derived exosomes: applications in regenerative medicine. Cells. 2021;10(8):1959. · DOI
  27. Tang N. Exosomes in multiple sclerosis and Alzheimer’s disease–adversary and ally. Biomed J. 2024;47(5):100665. · DOI
  28. Gao J, Li A, Hu J, Feng L, Liu L, Shen Z. Recent developments in isolating methods for exosomes. Front Bioeng Biotechnol. 2023;10:1100892. · DOI
  29. Subha D, Harshnii K, Madhikiruba KG, Nandhini M, Tamilselvi KS. Plant derived exosome-like Nanovesicles: An updated overview. Plant Nano Biol. 2023;3:100022. · DOI
  30. Li Y, Yang YY, Ren JL, Xu F, Chen FM, Li A. Exosomes secreted by stem cells from human exfoliated deciduous teeth contribute to functional recovery after traumatic brain injury by shifting microglia M1/M2 polarization in rats. Stem Cell Res Ther. 2017;8:198. · DOI
  31. Williams AM, Bhatti UF, Brown JF, et al. Early single-dose treatment with exosomes provides neuroprotection and improves blood-brain barrier integrity in swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2020;88:207–18. · DOI
  32. Xie ZH, Liu Z, Zhang XR, et al. Wharton’s Jelly-derived mesenchymal stem cells alleviate memory deficits and reduce amyloid-β deposition in an APP/PS1 transgenic mouse model. Clin Exp Med. 2016;16:89–98. · DOI
  33. Nakano M, Kubota K, Kobayashi E, et al. Bone marrow-derived mesenchymal stem cells improve cognitive impairment in an Alzheimer’s disease model by increasing the expression of microRNA-146a in hippocampus. Sci Rep. 2020;10:10772. · DOI
  34. Reza Z, Edwin E, Hernandez S, et al. Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer’s disease. Neural Regen Res. 2019;14:1626–34. · DOI · Paper page
  35. Chen HX, Liang FC, Gu P, et al. Exosomes derived from mesenchymal stem cells repair a Parkinson’s disease model by inducing autophagy. Cell Death Dis. 2020;11:288. · DOI · Paper page
  36. Xiaomin X, Zongshan L, Huirong Z, Chen H, Yaxing G. Mesenchymal stem cell-derived exosomes altered neuron cholesterol metabolism via Wnt5a-LRP1 axis and alleviated cognitive impairment in a progressive Parkinson’s disease model. Neurosci Lett. 2022;787:136810. · DOI
  37. Li Z, Liu F, He X, Yang X, Shan F, Feng J. Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia. Int Immunopharmacol. 2019;67:268–80. · DOI
  38. Wu XY, Liao BY, Xiao D, Wu WC, et al. Encapsulation of bryostatin-1 by targeted exosomes enhances remyelination and neuroprotection effects in the cuprizone-induced demyelinating animal model of multiple sclerosis. Biomater Sci. 2022;10:714–27. · DOI
  39. Xu H, Zhao G, Zhang Y, et al. Mesenchymal stem cell-derived exosomal microrna-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2. Stem Cell Res Ther. 2019;10:381. · DOI
  40. Lili Xu, Cao H, Xie Yi, Zhang Y, Mingyang Du, Xiaohui Xu, Ye R, Liu X. Exosome-shuttled miR-92b-3p from ischemic preconditioned astrocytes protects neurons against oxygen and glucose deprivation. Brain Res. 2019;1717:66–73. · DOI
  41. Chen KH, Chen C, Wallace CG, et al. Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke. Oncotarget. 2016;7:74537–56. · DOI
  42. Lee M, Liu T, Im W, Kim M. Exosomes from adipose-derived stem cells ameliorate phenotype of Huntington’s disease in vitro model. Eur J Neurosci. 2016;44:2114–9. · DOI · Paper page
  43. Long Q, Upadhya D, Hattiangady B, Kim DK, An SY, Shuai B, Prockop DJ, Shetty AK. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc Natl Acad Sci. 2017;114:E3536–45. · DOI
  44. Kodali M, Castro OW, Kim DK, et al. Intranasally administered human MSC-derived extracellular vesicles pervasively incorporate into neurons and microglia in both intact and status epilepticus injured forebrain. Int J Mol Sci. 2020;21:181. · DOI
  45. Murphy MP, LeVine H. Alzheimer’s disease and the amyloid-beta peptide. J Alzheimer’s Dis. 2010;1:311–23. · DOI · Paper page
  46. Liu W, Bai X, Zhang A, Huang J, Xu S, Zhang J. Role of exosomes in central nervous system diseases. Front Mol Neurosci. 2019;12:240. · DOI
  47. Mycko MP, Baranzini SE. microRNA and exosome profiling in multiple sclerosis. Mult Scler. 2020;26:599–604. · DOI
  48. Merve B, Necmeddin G, Bahar S, et al. Dual action of exosomes derived from in vitro Aβ toxicity model: The role of age for pathological response. Arch Gerontol Geriatr. 2023;106:104874. · DOI
  49. Mathew B, Mansuri MS, Williams KR, Nairn AC. Exosomes as emerging biomarker tools in neurodegenerative and neuropsychiatric disorders—a proteomics perspective. Brain Sci. 2021;11:258. · DOI
  50. Huber CC, Callegari EA, Paez MD, Romanova S, Wang H. Heat shock-induced extracellular vesicles derived from neural stem cells confer marked neuroprotection against oxidative stress and amyloid-β-caused neurotoxicity. Mol Neurobiol. 2022;59:7404–12. · DOI
  51. Cui GH, Guo HD, Li H, et al. RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease. Immun Ageing. 2019;16:10. · DOI
  52. Huo L, Du X, Li X, Liu S, Xu Y. The emerging role of neural cell-derived exosomes in intercellular communication in health and neurodegenerative diseases. Front Neurosci. 2021;15:738442. · DOI
  53. Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front Public Health. 2021;9:776847. · DOI
  54. Mavroeidi P, Vetsi M, Dionysopoulou D, Xilouri M. Exosomes in alpha-synucleinopathies: propagators of pathology or potential candidates for nanotherapeutics? Biomolecules. 2022;12:957. · DOI
  55. Yu H, Sun T, An J, Wen L, Liu F, Bu Z, Cui Y, Feng J. Potential roles of exosomes in Parkinson’s disease: from pathogenesis, diagnosis, and treatment to prognosis. Front Cell Dev Biol. 2020;8:86. · DOI
  56. Kojima R, Bojar D, Rizzi G, Hamri GC, El Baba MD, Saxena P, Ausländer S, Tan KR, Fussenegger M. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nat Commun. 2018;9:1305. · DOI · Paper page
  57. Yi S, Wang L, Wang H, Ho MS, Zhang S. Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective. Int J Mol Sci. 2022;23:14753. · DOI
  58. Cooper JM, Wiklander PB, Nordin JZ, Al-Shawi R, et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord. 2014;29:1476–85. · DOI
  59. Chugh C. Acute ischemic stroke: management approach. Indian J Crit Care Med. 2019;23:S140–6. · DOI
  60. Jiang L, Chen W, Ye J, Wang Y. Potential role of exosomes in ischemic stroke treatment. Biomolecules. 2022;12:115. · DOI
  61. Xin H, Li Y, Liu Z, Wang X, Shang X, Cui Y, et al. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells. 2013;31:2737–46. · DOI
  62. Pei X, Li Y, Zhu L, Zhou Z. Astrocyte-derived exosomes transfer miR-190b to inhibit oxygen and glucose deprivation-induced autophagy and neuronal apoptosis. Cell Cycle. 2020;19:906–17. · DOI
  63. Xiaowen H, Jiaji P, Yongfang L, et al. Extracellular vesicles from adipose-derived stem cells promote microglia M2 polarization and neurological recovery in a mouse model of transient middle cerebral artery occlusion. Stem Cell Res Ther. 2022;13:21. · DOI
  64. Liu Y, Fu N, Su J, Wang X, Li X. Rapid Enkephalin Delivery Using Exosomes to Promote Neurons Recovery in Ischemic Stroke by Inhibiting Neuronal p53/Caspase-3. Biomed Res Int. 2019;4:4273290.
  65. Shen H, Yao X, Li H, Li X, Zhang T, Sun Q, Ji C, Chen G. Role of exosomes derived from miR-133b modified MSCs in an experimental rat model of intracerebral hemorrhage. J Mol Neurosci. 2018;64(3):421–30. · DOI
  66. Xiao Y, Geng F, Wang G, Li X, Zhu J, Zhu W. Bone marrow-derived mesenchymal stem cells-derived exosomes prevent oligodendrocyte apoptosis through exosomal miR-134 by targeting caspase-8. J Cell Biochem. 2019;120:2109–18. · DOI
  67. Deng Y, Duan R, Ding W, Gu Q, Liu M, Zhou J, Sun J, Zhu J. Astrocyte-derived exosomal nicotinamide phosphoribosyltransferase (Nampt) ameliorates ischemic stroke injury by targeting AMPK/mTOR signaling to induce autophagy. Cell Death Dis. 2022;13:1057. · DOI
  68. Zhao J, Deng H, Xun C, Chen C, Hu Z, Ge L, Jiang Z. Therapeutic potential of stem cell extracellular vesicles for ischemic stroke in preclinical rodent models: a meta-analysis. Stem Cell Res Ther. 2023;14:62. · DOI
  69. Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19:1–10.
  70. Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. 2017;140:527–46.
  71. Zheng X, Sun K, Liu Y, Yin X, Zhu H, Yu F, Zhao W. Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia. J Control Release. 2023;353:675–84. · DOI
  72. Zhuang X, Xiang X, Grizzle W, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther. 2011;19:1769–79. · DOI · Paper page
  73. Zhai Y, Wang Q, Zhu Z, et al. High-efficiency brain-targeted intranasal delivery of BDNF mediated by engineered exosomes to promote remyelination. Biomater Sci. 2022;10:5707–18. · DOI
  74. Tran S, Bielle F. WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification. Curr Opin Oncol. 2022;34:670–5.
  75. McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34:981–98. · DOI
  76. Ioele G, Chieffallo M, Occhiuzzi MA, De Luca M, Garofalo A, Ragno G, et al. Anticancer drugs: recent strategies to improve stability profile, pharmacokinetic and pharmacodynamic properties. Molecules. 2022;27:5436. · DOI
  77. Lee Y, Kim M, Ha J, Lee M. Brain-targeted exosome-mimetic cell membrane nanovesicles with therapeutic oligonucleotides elicit anti-tumor effects in glioblastoma animal models. Bioeng Transl Med. 2023;8:e10426. · DOI
  78. Lee H, Bae K, Baek A-R, Kwon E-B, Kim Y-H, Nam S-W, et al. Glioblastoma-derived exosomes as nanopharmaceutics for improved glioma treatment. Pharmaceutics. 2022;14:1002. · DOI
  79. Zhilan Y, Tao Z, Wenshan H, Honglin J, Cuiwei L, Zhe Y, et al. Methotrexate-loaded extracellular vesicles functionalized with therapeutic and targeted peptides for the treatment of glioblastoma multiforme. ACS Appl Mater Interfaces. 2018;10:12341–50. · DOI
  80. Zhang C, Song J, Lou L, Qi X, Zhao L, Fan B, et al. Doxorubicin-loaded nanoparticle coated with endothelial cells-derived exosomes for immunogenic chemotherapy of glioblastoma. Bioeng Transl Med. 2020;6:e10203. · DOI
  81. Adamus T, Hung C-Y, Yu C, Kang E, Hammad M, Flores L, et al. Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells. Mol Ther Nucleic Acids. 2022;27:611–20. · DOI
  82. Huang Z, Keramat S, Izadirad M, Chen Z-S, Soukhtanloo M. The potential role of exosomes in the treatment of brain tumors, recent updates and advances. Front Oncol. 2022;12:869929. · DOI
  83. Li DB, Liu JL, Wang W, Luo XM, et al. Plasma exosomal miRNA-122-5p and miR-300-3p as potential markers for transient ischaemic attack in rats. Front Aging Neurosci. 2018;10:24. · DOI
  84. Chanteloup G, Cordonnier M, Moreno-Ramos T, Pytel V, Matías-Guiu J, Gobbo J, et al. Exosomal HSP70 for monitoring of frontotemporal dementia and Alzheimer’s disease: Clinical and FDG-PET correlation. J Alzheimers Dis [Internet]. 2019;71(4):1263–9. · DOI
  85. Goetzl EJ, Schwartz JB, Abner EL, Jicha GA, Kapogiannis D. High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Ann Neurol. 2018;83(3):544–52. · DOI
  86. Zheng H, Xie Z, Zhang X, Mao J, Wang M, Wei S, et al. Investigation of α-Synuclein species in plasma exosomes and the oligomeric and phosphorylated α-Synuclein as potential peripheral biomarker of Parkinson’s disease. Neuroscience [Internet]. 2021;469:79–90. · DOI
  87. Cao X-Y, Lu J-M, Zhao Z-Q, Li M-C, Lu T, An X-S, et al. MicroRNA biomarkers of Parkinson’s disease in serum exosome-like microvesicles. Neurosci Lett. 2017;644:94–9. · DOI
  88. Ebrahimkhani S, Vafaee F, Young PE, Hur SSJ, Hawke S, Devenney E, et al. Exosomal microRNA signatures in multiple sclerosis reflect disease status. Sci Rep. 2017;7(1):14293. · DOI
  89. Lin Z, Gu Y, Zhou R, Wang M, Guo Y, Chen Y, et al. Serum exosomal proteins F9 and TSP-1 as potential diagnostic biomarkers for newly diagnosed epilepsy. Front Neurosci. 2020;14:737. · DOI
  90. Guedes VA, Kenney K, Shahim P, Qu B-X, Lai C, Devoto C, et al. Exosomal neurofilament light: A prognostic biomarker for remote symptoms after mild traumatic brain injury? Neurology 2020;94(23):e2412–23. · DOI
  91. Waseem A, Saudamini, Haque R, Janowski M, Raza SS. Mesenchymal stem cell-derived exosomes: Shaping the next era of stroke treatment. Neuroprotection. 2023;1(2):99–116. · DOI
  92. Nguyen Cao TG, Kang JH, Kang SJ, Truong Hoang Q, Kang HC, Rhee WJ, et al. Brain endothelial cell-derived extracellular vesicles with a mitochondria-targeting photosensitizer effectively treat glioblastoma by hijacking the blood-brain barrier. Acta Pharm Sin B. 2023;13(9):3834–48. · DOI
  93. Zhao J, Li Y, Jia R, Wang J, Shi M, Wang Y. Mesenchymal stem cells-derived exosomes as dexamethasone delivery vehicles for autoimmune hepatitis therapy. Front Bioeng Biotechnol. 2021;9:650376. · DOI
  94. Rehman FU, Liu Y, Yang Q, Yang H, Liu R, Zhang D, et al. Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy. J Control Release. 2022;345:696–708. · DOI
  95. Lu Y, Huang W, Li M, Zheng A. Exosome-based carrier for RNA delivery: Progress and challenges. Pharmaceutics. 2023;15(2):598. · DOI
  96. Markov O, Oshchepkova A, Mironova N. Immunotherapy based on dendritic cell-targeted/-derived extracellular vesicles-A novel strategy for enhancement of the anti-tumor immune response. Front Pharmacol. 2019;10:1152. · DOI
  97. Fan J, Han Y, Sun H, Sun S, Wang Y, Guo R, et al. Mesenchymal stem cell-derived exosomal microRNA-367–3p alleviates experimental autoimmune encephalomyelitis via inhibition of microglial ferroptosis by targeting EZH2. Biomed Pharmacother. 2023;162:114593. · DOI
  98. Shiue S-J, Rau R-H, Shiue H-S, Hung Y-W, Li Z-X, Yang KD, et al. Mesenchymal stem cell exosomes as a cell-free therapy for nerve injury-induced pain in rats. Pain. 2019;160(1):210–23. · DOI
  99. Singh G, Mehra A, Arora S, Gugulothu D, Vora LK, Prasad R, et al. Exosome-mediated delivery and regulation in neurological disease progression. Int J Biol Macromol. 2024;264(130728):130728. · DOI
  100. Liang Y, Iqbal Z, Lu J, Wang J, Zhang H, Chen X, Duan L, Xia J. Cell-derived nanovesicle-mediated drug delivery to the brain: Principles and strategies for vesicle engineering. Mol Ther. 2023;31(5):1207–24. · DOI · Paper page
  101. Wang Y-Y, Cheng J, Liu Y-D, Wang Y-P, Yang Q-W, Zhou N. Exosome-based regenerative rehabilitation: A novel ice breaker for neurological disorders. Biomed Pharmacother. 2023;169(115920):115920. · DOI
  102. Logozzi M, Orefice NS, Raimo D, Mizzoni R, Fais D. The importance of detecting, quantifying, and characterizing exosomes as a new diagnostic/prognostic approach for tumor patients. Cancers (Basel). 2023;15(11):2878. · DOI
  103. Xie X, Song Q, Dai C, Cui S, Tang R, Li S, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer’s disease: a phase I/II clinical trial. Gen Psychiatr. 2023;36(5):e101143. · DOI
  104. Zanirati G, Dos Santos PG, Alcará AM, Bruzzo F, Ghilardi IM, Wietholter V, et al. Extracellular vesicles: The next generation of biomarkers and treatment for central nervous system diseases. Int J Mol Sci. 2024;25(13):7371. · DOI
  105. Valsecchi C, Croce S, Lenta E, Acquafredda G, Comoli P, Avanzini MA. New therapeutic approaches in pediatric diseases: Mesenchymal stromal cell and mesenchymal stromal cell-derived extracellular vesicles as new drugs. Pharmacol Res. 2023;192(106796):106796. · DOI
  106. Li Y-J, Wu J-Y, Liu J, Xu W, Qiu X, Huang S, et al. Artificial exosomes for translational nanomedicine. J Nanobiotechnology. 2021;19(1):242. · DOI · Paper page
  107. Zhu L, Sun H-T, Wang S, Huang S-L, Zheng Y, Wang C-Q, et al. Isolation and characterization of exosomes for cancer research. J Hematol Oncol. 2020;13(1):152. · DOI
  108. Dad HA, Gu TW, Zhu AQ, Huang LQ, Peng LH. Plant exosome-like nanovesicles: emerging therapeutics and drug delivery nanoplatforms. Mol Ther. 2021;29:13–31. · DOI

Cited by

Sorted by citations

See all 34

Metadata

Authors
Vahab, S. A., V, V. K., & Kumar, V. S.
Venue
Drug Delivery and Translational Research
Publisher
Springer Science and Business Media LLC
Published
2024-09-26
Volume
15
Issue
4
Pages
1121-1138
ISSN
  • 2190-393X
  • 2190-3948
DOI
10.1007/s13346-024-01710-x
Cited by
34
References
17
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review